Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70
正文 · 原文
An important question for KEYNOTE-B49 at #ESMO26:
KEYNOTE-756 is exploring pembrolizumab earlier in HR+/HER2− breast cancer.
If perioperative immunotherapy becomes standard, how relevant will B49 be to patients relapsing after prior PD-1 exposure?
B49 excluded these patients.
55 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com